Influenza Virus: Immunity and Vaccination Strategies. Comparison of the Immune Response to Inactivated and Live, Attenuated Influenza Vaccines

Scandinavian Journal of Immunology

Volumn 59, Issue 1, 2004, Pages 1-15

  Cox, R J ^a   Brokstad, K A ^b   Ogra, P ^c  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIVIRUS AGENT; BACTERIAL TOXIN; DNA VACCINE; ENTEROTOXIN; IMMUNOGLOBULIN A ANTIBODY; INACTIVATED VACCINE; INFLUENZA VACCINE; LIVE VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; OSELTAMIVIR; PRASTERONE; PROTEASOME; QS 21; QS 7; RIMANTADINE; RNA DERIVATIVE; SAPONIN; TRIPLE VACCINE; VIROSOME; ZANAMIVIR;

ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; CAPSULE FILLING; CELLULAR IMMUNITY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; COMMERCIAL PHENOMENA; DIARRHEA; DRUG COST; DRUG EFFECT; DRUG FORMULATION; DRUG SAFETY; EMULSION; EPIDEMIOLOGICAL DATA; ERYTHEMA; GASTROINTESTINAL DISEASE; HEALTH CARE COST; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNE SYSTEM; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS; MUCOSA; NAUSEA; NONHUMAN; NOSE DISEASE; OLFACTORY SYSTEM; PATHOGENESIS; POWDER; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; REVIEW; SIDE EFFECT; SINUSITIS; SKIN MANIFESTATION; SYRUP; SYSTEMIC DISEASE; TABLET; VIRUS TRANSMISSION; VOMITING;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; ADULT; AGED; ANIMALS; CHILD; FEMALE; HUMANS; INFLUENZA VACCINES; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRIDAE INFECTIONS; VACCINES, ATTENUATED; VACCINES, INACTIVATED;

EID: 0442323299     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0300-9475.2004.01382.x     Document Type: Review

References (123)

1. Wright PF, Webster RG. Orthomyxoviruses. In: Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE, eds. Fields Virology, 4th edn. Philadelphia, PA: Lippincott Williams & Wilkins, 2001, 1533-79 [Chapter 47].
2. Webster RG, Bean WJ. Evolution and ecology of influenza viruses: interspecies transmission. In: Nicholson KG, Webster KG, Hay A, eds. Textbook of Influenza. Oxford, UK: Blackwell Science, 1998, 109-19.
3. Taubenberger JK, Reid AH, Krafft AE, Bijwaard KE, Fanning TG. Initial genetic characterization of the 1918 'Spanish' influenza virus. Science 1997;21:1793-6.
4. Yasuda J, Shortridge KF, Shimizu Y, Kida H. Related molecular evidence for a role of domestic ducks in the introduction of avian H3 influenza viruses to pigs in southern China, where the A/Hong Kong/68 (H3N2) strain emerged. J Gen Virol 1991;72:2007-10.
5. Scholtissek C, Hinshaw VS, Olsen CW. Influenza in pigs and their role as intermediate host. In: Nicholson KG, Webster KG, Hay A, eds. Textbook of Influenza. Oxford, UK: Blackwell Science, 1998, 137-45.
6. Lui K-J, Kendal AP. Impact of influenza epidemics on mortality in the United States from October 1972 to May 1985. Am J Public Health 1987;77:712-6.
7. Simonsen L, Schonberger LB, Stroup DF, Arden NH, Cox NJ. Impact of influenza on mortality in the USA. In: Brown LE, Hampson AW, Webster RG, eds. Options for the Control of Influenza III. New York, NY: Elsevier Science, 1996, 26-33.
8. Brammer TL, Murray EL, Fukuda K, Hall HE, Klimov A, Cox NJ. Surveillance for influenza in the United States, 1997-98, 1998-99, and 1999-00 seasons. MMWR CDC Surveill Summ 2002;51:1-10.
9. Meltzer MI, Cox NJ, Fukuda K. The economic impact of pandemic influenza in the United States: priorities for intervention. Emerg Infect Dis 1999;5:659-71.
10. Blitz SG. Developments in the care of influenza patients: priorities and perspectives. JCOM 2000;7:63-74.
11. Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2003;52:1-34 [No. RR-8].
12. WHO. Manual on animal influenza diagnosis and surveillance (WHO/CDS/CSR/NCS/2002.5) (available from: http://www.who.int/).
13. Centers for Disease Control and Prevention. Guideline for infection control in healthcare personnel, 1998. Infect Control Hosp Epidemiol 1998;19:410-59.
14. Couch RB. Advances in influenza virus vaccine research. Ann N Y Acad Sci 1993;685:803-12.
15. Beyer WE, Palache AM, de Jong JC, Osterhaus AD. Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis. Vaccine 2002;20:1340-53.
16. Glezen WP, Taber LH, Frank AL, Gruber WC, Piedra PA. Influenza virus infection in infants. Pediatr Infect Dis J 1997;16:1065-8.
17. Chiu SS, Lau TL, Chan KH, Wong WHS, Peiris JSM. Influenza related hospitalizations among children in Hong Kong. N Engl J Med 2002;347:2097-103.
18. Powers DC, Smith GE, Anderson EL et al. Influenza A virus vaccines containing purified recombinant H3 hemagglutinin are well tolerated and induce protective immune responses in healthy adults. J Infect Dis 1995;171:1595-9.
19. Van Essen GA, Palache AM, Forleo E, Fedson DS. Influenza vaccination in 2000: recommendations and vaccine use in 50 developed and rapidly countries. Vaccine 2003;21:1780-5.
20. Murphy BR, Chalhub EG, Nusinoff SR, Kasel J, Chanock RM. Temperature-sensitive mutants of influenza virus. III. Further characterization of the ts-[E] influenza A recombinant (H3N2) virus in man. J Infect Dis 1973;128:479-87.
21. Clements ML, O'Donnell S, Levine MM, Chanock RM, Murphy BR, Dose response of A/Alaska/6/77 (H3N2) cold-adapted reassortant vaccine virus in adult volunteers: role of local antibody in resistance to infection with vaccine virus. Infect Immun 1983;40:1044-51.
22. Clements ML, Betts RF, Tierney EI, Murphy BR. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol 1986;24:157-60.
23. Clements ML, Murphy BR. Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza. A virus vaccine. J Clin Microbiol 1986;23:66-72.
24. Potter CW. Chronicle of influenza pandemics. In: Nicholson KG, Webster KG, Hay A, eds. Textbook of Influenza. Oxford, UK: Blackwell Science, 1998, 3-18.
25. Noble GR. Epidemiological and clinical aspects of influenza. In: Beare AS, ed. Basic and Applied Influenza Research. Boca Raton, FL: CRC Press, 1982, 1179.
26. Cretescu L, Beare AS, Schild GC. Formation of antibody to matrix protein in experimental human influenza A virus infections. Infect Immun 1978;22:322-7.
27. Potter CW, Oxford JS. Determinants of immunity to influenza infection in man. Br Med J 1979;35:69-75.
28. Askonas BA, McMichael AJ, Webster RG. The immune response to influenza viruses and the problem of protection against infection. In: Beare AS, ed. Basic and Applied Influenza Research. Boca Raton, FL: CRC Press, 1982, 159-88.
29. Artenstein MS, Bellanti JA, Buescher EL. Identification of the antiviral substances in nasal secretions. Proc Soc Exp Biol Med 1964;117:558-64.
30. Mazanec MB, Coudret CL, Fletcher DR. Intracellular neutralization of influenza virus by immunoglobulin A anti-hemagglutinin monoclonal antibodies. J Virol 1995:69:1339-44.
31. Rossen RD, Butler WT, Waldman RH et al. The proteins in nasal secretion. II. A longitudinal study of IgA and neutralizing antibody levels in nasal washings from men infected with influenza virus. JAMA 1970;211:1157-61.
32. Murphy BR, Clements ML. The systemic and mucosal immune response of humans to influenza A virus. In: Mestecky J, McGhee JR, eds. Current Topics in Microbiology and Immunology. New York, NY: Springer Verlag, 1989, 107-16.
33. Wright PF, Murphy BR, Kervina M, Lawrence EM, Phelan MA, Karzon DT. Secretory immunological response after intranasal inactivated influenza A virus vaccinations: evidence for immunoglobulin A memory. Infect Immun 1983;40:1092-5.
34. Brokstad KA, Cox RJ, Eriksson JC, Olofsson J, Jonsson R, Davidsson A. High prevalence of influenza specific antibody secreting cells in nasal mucosa. Scand J Immunol 2001;54:243-7.
35. Cox NJ, Subbarao K. Influenza. Lancet 1999;354:1277-82.
36. Cox RJ, Brokstad KA, Zuckerman MA, Wood JM, Haaheim LR, Oxford JS. An early humoral immune response in peripheral blood following parenteral inactivated influenza vaccination. Vaccine 1994;12:993-9.
37. Callard RE. Specific in vitro antibody response to influenza virus by human blood lymphocytes. Nature (London) 1979;282:734-6.
38. Yarchoan R, Murphy BR, Strober W, Schneider HS, Nelson DL. Specific anti-influenza virus antibody production in vitro by human peripheral blood mononuclear cells. J Immunol 1981;127:2558-94.
39. Couch RB, Kasel JA. Immunity to influenza in man. Annu Rev Microbiol 1983;37:529-49.
40. Brown TA, Murphy BR, Radl J, Haaijman JJ, Mestecky J. Subclass distribution and molecular form of immunoglobulin A hemagglutinin antibodies in sera and nasal secretions after experimental secondary infection with influenza A virus in humans. J Clin Microbiol 1985;22:259-64.
41. Jurgensen PF, Olsen GN, Johnson JE III et al. Immune response of the human respiratory tract. II. Cell-mediated immunity in the lower respiratory tract to tuberculin and mumps and influenza viruses. J Infect Dis 1973;128:730-5.
42. Yewdell JW, Hackett CJ. The specificity and function of T lymphocytes induced by influenza A viruses. In: Krug R, ed. The Influenza Viruses. New York, NY: Plenum Press, 1989.
43. Quinnan GV, Ennis FA, Tuazon CU et al. Cytotoxic lymphocytes and antibody-dependent complement-mediated cytotoxicity induced by administration of influenza vaccine. Infect Immun 1980;30:362-9.
44. Ruben FL, Bachmayer H, Fireman P. Parameters of humoral and cellular immunity to influenza A/USSR/90/77(H1N1): virus in various age groups. J Infect Dis 1980;142:699-703.
45. McMichael AJ, Gotch FM, Noble GR, Beare PAS. Cytotoxic T-cell immunity to influenza. N Engl J Med 1983;309:13-7.
46. McMichael AJ, Michie CA, Gotch FM, Smith GL, Moss B. Recognition of influenza A virus nucleoprotein by human cytotoxic T lymphocytes. J Gen Virol 1986;67:719-26.
47. Ennis FA, Rook AH, Yi-Hua QY et al. HLA-restricted virus-specific cytotoxic T-lymphocyte responses to live and inactivated influenza vaccines. Lancet 1981;2:887-91.
48. Fleischer B, Becht H, Rott R. Recognition of viral antigens by human influenza A virus-specific T lymphocyte clones. J Immunol 1985;135:2800-4.
49. Ennis FA, Yi-Hua Q, Schild GC. Antibody and cytotoxic T lymphocyte responses of humans to live and inactivated influenza vaccines. J Gen Virol 1982;58:273-81.
50. + T cell responses to the influenza A viruses. In: Osterhaus A, Cox NJ, Hampson AW, eds. Options for the Control of Influenza IV. New York, NY: Elsevier Science, 2001, 293-300.
51. + T and B cells in influenza virus infection. In: Osterhaus A, Cox NJ, Hampson AW, eds. Options for the Control of Influenza IV. New York, NY: Elsevier Science, 2001, 311-8.
52. Nguyen HH, van Ginkel FW, Vu HL, McGhee JR, Mestecky J. Mechanism of heterosubtypic immunity to influenza A virus infection. In: Osterhaus A, Cox NJ, Hampson AW, eds. Options for the Control of Influenza IV. New York, NY: Elsevier Science, 2001, 333-40.
53. Kilbourne ED, Couch RB, Kasel JA et al. Purified influenza A virus N2 neuraminidase vaccine is immunogenic and non-toxic in humans. Vaccine 1995;13:1799-803.
54. Glück R, Wegmann A. Liposomal presentation of influenza antigens. In: Nicholson KG, Webster RG, Hay AJ, eds. Textbook of Influenza. Oxford, UK. Blackwell Science, 1998, 373-90.
55. Crovari P, Garbino E, Bruzzone B, Herzog C, Glück R. Intranasal influenza vaccine: protective efficacy in children and adults. In: Osterhaus A, Cox NJ, Hampson AW, eds. Options for the Control of Influenza IV. New York, NY: Elsevier Science, 2001, 965-8.
56. Glück R. Preclinical and clinical evaluation of a new virosomal intranasal influenza vaccine. In: Osterhaus A, Cox NJ, Hampson AW, eds. Options for the Control of Influenza IV. New York, NY: Elsevier Science, 2001, 969-78.
57. Plante M, Joned D, Allard F et al. Nasal proteosome subunit flu vaccine elicits mucosal IgA, serum HAI and protection comparable to conventional injectable flu vaccine. In: Osterhaus A, Cox NJ, Hampson AW, eds. Options for the Control of Influenza IV. New York, NY: Elsevier Science, 2001, 979-84.
58. Webster RG. DNA vaccination: a potential future strategy. In: Nicholson KG, Webster RG, Hay AJ, eds. Textbook of Influenza. Oxford, UK: Blackwell Science, 1998, 410-21.
59. Ignuzzi M, Gerbaud S, van der Werf S, Escriou N. Replicons from positive strand RNA viruses for naked RNA immunization against influenza. In: Osterhaus A, Cox NJ, Hampson AW, eds. Options for the Control of Influenza IV. New York, NY: Elsevier Science, 2001, 923-9.
60. Ott G, Barchfel GL, Van Nest G. Enhancement of humoral response against human influenza vaccine with simple submicron oil/water emulsion adjuvant MF59. Vaccine 1995;3:1557-62.
61. Wyde PR, Guzman E, Gilbert BE, Couch RB. Immunogenicity and protection in mice given inactivated influenza vaccine, MPL, QS-21 or QS-7. In: Osterhaus A, Cox NJ, Hampson AW, eds. Options for the Control of Influenza IV. New York, NY: Elsevier Science, 2001, 999-1005.
62. Tumpey TM, Clements JD, Karz JM. Mucosal vaccination protects mice against influenza A heterosubtypic challenge. In: Osterhaus A, Cox NJ, Hampson AW, eds. Options for the Control of Influenza IV. New York, NY: Elsevier Science, 2001, 985-92.
63. Danenberg HD, Ben-Yehuda A, Zakay-Rones Z, Friedman G. Deydroepiandroesterone (DHEA) treatment reverses the impaired immune response of old mice to influenza vaccination and protects from influenza infection. Vaccine 1995;13:1445-8.
64. Ahmed FA, Singleton JA, Franks AL. Influenza vaccination for healthy adults. N Engl J Med 2001;345:1543-7.
65. Nichol KL. Efficacy/clinical effectiveness of inactivated influenza vaccines in adults. In: Nicholson KG, Webster RG, Hay AJ, eds. Textbook of Influenza. Oxford, UK Blackwell Science, 1998a, 358-72.
66. Gross PA, Hermongenes AW, Sacks HS, Lau J, Levandowski RA. Efficacy of influenza vaccines in elderly persons: a meta-analysis and review of the literature. Ann Intern Med 1995;123:518-27.
67. Nichol KL, Wuorenms J, Von Sternberg T. Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Arch Intern Med 1998b;158:1769-76.
68. Zuckerman M, Cox R, Taylor J, Wood J, Haaheim L, Oxford J. Rapid immune response to influenza vaccination. Lancet 1993;342:1113.
69. Oxford JS, Schild GC, Potter CW, Jennings R. Specificity of the anti-haemagglutinin antibody response induced in man by inactivated influenza vaccine and by natural infection. J Hyg 1979;82:51-61.
70. La Montague JR, Noble GR, Quinnan GV et al. Summary of clinical trials of inactivated influenza vaccines - 1978. Rev Infect Dis 1983;5:723-36.
71. Daubeney P, Taylor CJ, McGaw J et al. Immunogenicity and tolerability of a trivalent influenza subunit vaccine (Influvac) in high-risk children aged 6 months to 4 years. Br J Clin Pract 1997;51:87-90.
72. Gonzalez M, Pirez MC, Wars E, Dibarbourne J, Garcia A, Picolet H. Safety and immunogenicity of a paediatric presentation of an influenza vaccine. Arch Dis Child 2000;83:488-91.
73. Brokstad KA, Cox RJ, Olofsson J, Jonsson R, Haaheim LR. Parenteral influenza vaccination induces a rapid systemic and local immune response. J Infect Dis 1995;171:198-203.
74. Brokstad KA, Cox RJ, Major D, Wood JM, Haaheim LR. Cross-reaction but no avidity change of the serum antibody response after influenza vaccination. Vaccine 1995;13:1522-8.
75. El-Madhun AS, Cox RJ, Soreide A, Olofsson J, Haaheim LR. Systemic and mucosal immune responses in young children and adults after parenteral influenza vaccination. J Infect Dis 1998;178:933-9.
76. El-Madhun AS, Cox RJ, Haaheim LR. The effect of age and natural priming on the IgG and IgA subclass responses after parenteral influenza vaccination. J Infect Dis 1999;180:1356-60.
77. Cox RJ, Brokstad KA. The postvaccination antibody response to influenza virus proteins. APMIS 1999;107:289-96.
78. Brokstad KA, Cox RJ, Oxford JS, Haaheim LR. IgA, IgA subclasses, and secretory component levels in oral fluid collected from subjects after parental influenza vaccination. J Infect Dis 1995;171:1072-4.
79. Brokstad KA, Eriksson JC, Cox RJ et al. Parenteral vaccination against influenza does not induce a local antigen-specific immune response in the nasal mucosa. J Infect Dis 2002;185:878-84.
80. Eriksson JC, Davidsson A, Garberg H, Brokstad KA. Lymphocyte distribution in the tonsils prior to and after influenza vaccination. Vaccine 2003;22:57-63.
81. El-Madhun AS, Cox RJ, Seime A, Sovik O, Haaheim LR. Systemic and local immune responses after parenteral influenza vaccination in juvenile diabetic patients and healthy controls: results from a pilot study. Vaccine 1998;16:156-60.
82. Cox RJ, Mykkeltvedt E, Sjursen H, Haaheim LR. The effect of zanamivir treatment on the early immune response to influenza vaccination. Vaccine 2001;19:4743-9.
83. Ogra PL, Mestecky J, Lamm ME, Strober W, Bienstock J, McGhee JR, eds. Mucosal Immunology, 2nd edn. New York, NY: Academic Press, 1999.
84. Ogra PL, Faden H, Welliver RC. Vaccination strategies for mucosal immune responses. Clin Microbiol Rev 2001;14:430-45.
85. Abramson JS. Intranasal, cold-adapted, live, attenuated influenza vaccine. Pediatr Infect Dis J 1999;18:1103-4.
86. King JC, Lagos R, Bernstein DI et al. Safety and immunogenicity of low and high doses of trivalent live cold-adapted influenza vaccine administered intranasally as drops or spray to healthy children. J Infect Dis 1998;177:1394-7.
87. Mendelman PM, Cordova J, Cho I. Safety, efficacy and effectiveness of the influenza virus vaccine, trivalent, types A and B, live, cold-adapted (CAIV-T) in healthy children and healthy adults. Vaccine 2001;19:2221-6.
88. Murphy BR, Coelingh K. Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines. Viral Immunol 2002;15:295-323.
89. Wareing MD, Tannock GA. Live attenuated vaccines against influenza: an historical review. Vaccine 2001;19:3320-3.
90. Palese P, Garcia-Sastre A. Influenza vaccines: present and future. J Clin Invest 2002;110:9-13.
91. Potter CW, Jennings R, Clark A, Ali M. Interference following dual inoculation with influenza A (H3N2) and (H1N1) viruses in ferrets and volunteers. J Med Virol 1983;11:77-86.
92. Keitel WA, Couch RB, Quarles JM, Cate TR, Baxter B, Maassab HF. Trivalent attenuated cold-adapted influenza virus vaccine: reduced viral shedding and serum antibody responses in susceptible adults. J Infect Dis 1993;167:305-11.
93. Keitel WA, Piedra PA. Live cold-adapted, reassortant influenza vaccines (USA). In: Nicholson, KG, Webster RG, Hay AJ, eds. Textbook of Influenza. Oxford, UK: Blackwell Science, 1998, 373-90.
94. Swierkosz EM, Newman FK, Anderson EL, Nugent SL, Mills GB, Belshe RB. Multidose, live attenuated, cold-recombinant, trivalent influenza vaccine in infants and young children. J Infect Dis 1994;169:1121-4.
95. Belshe RB, Mendelman PM, Treanor J et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children. N Engl J Med 1998;338:1405-12.
96. Longini IM, Halloran ME, Nizam A et al. Estimation of the efficacy of live, attenuated influenza vaccine from a two-year, multi-center vaccine trial: implications for influenza epidemic control. Vaccine 2000;17:1902-9.
97. Belshe RB, Gruber WC, Mendelman PM et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis 2000a;181:1133-7.
98. Rudenko LG, Slepushkin AN, Monto AS et al. Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their unvaccinated contacts in Novgorod, Russia. J Infect Dis 1993;168:881-7.
99. Treanor JJ, Mattison HR, Dumyati G et al. Protective efficacy of combined live intranasal and inactivated influenza A virus vaccines in the elderly. Ann Intern Med 1992;117:625-33.
100. Edwards KM, Dupont WD, Westrich MK, Plummer WD Jr, Palmer PS, Wright PF. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis 1994;169:68-76.
101. Boyce TG, Poland GA. Promises and challenges of live-attenuated intranasal influenza vaccines across the age spectrum: a review. Biomed Pharmacother 2000;54:10-8.
102. Neuzil KM, Dupont WD, Wright PF, Edwards KM. Efficacy of inactivated and cold-adapted vaccines against influenza A infection, 1985 to 1990: the pediatric experience. Pediatr Infect Dis J 2001;20:733-40.
103. Piedra PA, Yan L, Kotloff K et al. Safety of the trivalent, cold-adapted influenza vaccine in preschool-aged children. Pediatrics 2002;110:662-72.
104. Johnson PR Jr, Feldman S, Thompson JM, Mahoney JD, Wright PF. Comparison of long-term systemic and secretory antibody responses in children given live, attenuated, or inactivated influenza A vaccine. J Med Virol 1985;17:325-35.
105. Boyce TG, Hsu HH, Sannella EC et al. Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults. Vaccine 2000;19:217-26.
106. Ada GL, Jones PD. The immune response to influenza infection. Curr Top Microbiol Immunol 1986;128:1-54.
107. Gruber WC, Taber LH, Glezen WP et al. Live attenuated and inactivated influenza vaccine in school-age children. Am J Dis Child 1990;144:595-600.
108. Gruber WC, Darden PM, Still JG, Lohr J, Reed G, Wright PF. Evaluation of bivalent live attenuated influenza A vaccines in children 2 months to 3 years of age: safety, immunogenicity and dose-response. Vaccine 1997;15:1379-84.
109. Powers DC, Sears SD, Murphy BR et al. Systemic and local antibody responses in elderly subjects given live or inactivated influenza A virus vaccines. J Clin Microbiol 1989;27:2666-71.
110. Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (London) 1972;70:767-77.
111. Kendal AP, Pereira MS, Skehel JJ. Concepts and Procedures for Laboratory Based Influenza Surveillance. Washington DC: US Department of Health and Human Services, 1982.
112. Heilman C, La Montagne JR. Influenza: status and prospects for its prevention, therapy, and control. Pediatr Clin North Am 1990;37:669-88.
113. Treanor JJ, Kotloff K, Betts RF et al. Evaluation of trivalent, live, cod-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine 1999;18:899-906.
114. Treanor JJ, Betts RF. Evaluation of live, cold-adapted influenza A and B virus vaccines in elderly and high-risk subjects. Vaccine 1998;16:1756-60.
115. Jackson LA, Holmes SJ, Mendelman PM, Huggins L, Cho I, Rhorer J. Safety of a trivalent live attenuated intranasal influenza vaccine, FluMist, administered in addition to parenteral trivalent inactivated influenza vaccine to seniors with chronic medical conditions. Vaccine 1999;17:1905-9.
116. Nichol KL. Live attenuated influenza virus vaccines: new options for the prevention of influenza. Vaccine 2001;19:4373-7.
117. Stepanova L, Naykhin A, Kolmskog C et al. The humoral response to live and inactivated influenza vaccines administered alone and in combination to young adults and elderly. J Clin Virol 2002;24:193-201.
118. Clements ML, Betts RF, Murphy BR. Advantage of live attenuated cold-adapted influenza A virus over inactivated vaccine for A/Washington/80 (H3N2) wild-type virus infection. Lancet 1984;1:705-8.
119. Monto AS, Davenport FM, Napier JA, Francis T Jr. Effect of vaccination of a school-age population upon the course of an A2-Hong Kong influenza epidemic. Bull World Health Organ 1969;41:537-42.
120. Monto AS, Davenport FM, Napier JA, Francis T Jr. Modification of an outbreak of influenza in Tecumseh, Michigan by vaccination of schoolchildren. J Infect Dis 1970;122:16-25.
121. Glezen WP, Couch RB. Interpandemic influenza in the Houston area, 1974-76. N Engl J Med 1978;298:587-92.
122. Munoz FM. The impact of influenza in children. Semin Pediatr Infect Dis 2002;13:72-8.
123. Nichol KL, Mendelman PM, Mallon KP et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomised controlled trial. JAMA 1999;282:137-44.